GSK

GSK is the London company left after the Haleon consumer-health spin, so Sensodyne and Centrum are no longer the core story. Shingrix is the shingles vaccine physicians recommend for older adults, and Arexvy competes with Pfizer's Abrysvo for the same RSV season.

ViiV Healthcare, which GSK controls alongside Pfizer and Shionogi, sells dolutegravir regimens such as Dovato and the long-acting injection Cabenuva. Gilead's single-tablet Biktarvy is the regimen most HIV clinics compare against those products.

Respiratory brands such as Trelegy still matter in primary care inhaler formularies, next to products from AstraZeneca and Boehringer Ingelheim. Vaccine volume, though, is set by pharmacy chains, public immunization programs, and how strongly a guideline prefers one brand.

Shingrix has few direct substitutes, so manufacturing yield and pharmacy stocking decide access.

Arexvy and Pfizer's Abrysvo split a seasonal adult RSV market that reopens with each guideline.

HIV treatment guidelines and clinic purchasing decide whether a patient starts on ViiV or on Gilead.

Older adults usually receive Shingrix at a pharmacy, where the fridge inventory is the practical limit.

HIV clinics that start patients on a single-tablet regimen rarely switch without a medical reason.